Lisa Maier

Prof. Lisa Maier

Chief, Division of Environmental and Occupational Health Sciences
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
ECElliott Crouser
Elliott Crouser
Lisa MaierLisa Maier
Lisa Maier
KWKevin C. Wilson
Kevin C. Wilson
CBCatherine A. Bonham
Catherine A. Bonham
AMAdam S. Morgenthau
Adam S. Morgenthau
RBRobert P. Baughman
Robert P. Baughman
Background: The diagnosis of sarcoidosis is not standardized but is based on three major criteria: a compatible clinical presentation, finding nonnecrotizing granulomatous inflammation in one or more tissue samples, and the exclusion of alternative causes of granulomatous disease. There are no universally accepted measures to determine if each diagnostic criterion has been satisfied; therefore, the diagnosis of sarcoidosis is never fully secure. Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize the best available evidence. The evidence was appraised using the Grading of Recommendations, Assessment, Development, and Evaluation approach and then discussed by a multidisciplinary panel. Recommendations for or against various diagnostic tests were formulated and graded after the expert panel weighed desirable and undesirable consequences, certainty of estimates, feasibility, and acceptability. Results: The clinical presentation, histopathology, and exclusion of alternative diagnoses were summarized. On the basis of the available evidence, the expert committee made 1 strong recommendation for baseline serum calcium testing, 13 conditional recommendations, and 1 best practice statement. All evidence was very low quality. Conclusions: The panel used systematic reviews of the evidence to inform clinical recommendations in favor of or against various diagnostic tests in patients with suspected or known sarcoidosis. The evidence and recommendations should be revisited as new evidence becomes available.

1 August 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
GRGanesh Raghu
Ganesh Raghu
MRMartine Remy-Jardin
Martine Remy-Jardin
CRChristopher J. Ryerson
Christopher J. Ryerson
JMJeffrey L. Myers
Jeffrey L. Myers
MKMichael Kreuter
Michael Kreuter
KWKevin C. Wilson
Kevin C. Wilson
Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It represents a collaborative effort among the American Thoracic Society, Japanese Respiratory Society, and Asociación Latinoamericana del Tórax. Methods: Systematic reviews were performed for six questions. The evidence was discussed, and then recommendations were formulated by a multidisciplinary committee of experts in the field of interstitial lung disease and HP using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Results: The guideline committee defined HP, and clinical, radiographic, and pathological features were described. HP was classified into nonfibrotic and fibrotic phenotypes. There was limited evidence that was directly applicable to all questions. The need for a thorough history and a validated questionnaire to identify potential exposures was agreed on. Serum IgG testing against potential antigens associated with HP was suggested to identify potential exposures. For patients with nonfibrotic HP, a recommendation was made in favor of obtaining bronchoalveolar lavage (BAL) fluid for lymphocyte cellular analysis, and suggestions for transbronchial lung biopsy and surgical lung biopsy were also made. For patients with fibrotic HP, suggestions were made in favor of obtaining BAL for lymphocyte cellular analysis, transbronchial lung cryobiopsy, and surgical lung biopsy. Diagnostic criteria were established, and a diagnostic algorithm was created by expert consensus. Knowledge gaps were identified as future research directions. Conclusions: The guideline committee developed a systematic approach to the diagnosis of HP. The approach should be reevaluated as new evidence accumulates.

18 April 2014
Verified
Journal Article
Closed access
Marc JudsonMarc Judson
Marc Judson
UCUlrich Costabel
Ulrich Costabel
MDMarjolein Drent
Marjolein Drent
AWAthol U Wells
Athol U Wells
Lisa MaierLisa Maier
Lisa Maier
TIThe Wasog Sarcoidosis Organ Assessment Instrument Investigators
The Wasog Sarcoidosis Organ Assessment Instrument Investigators

1 August 2016 in Chest
Verified
Journal Article
Closed access
HLHongbo Liu
Hongbo Liu
DPDivya Patel
Divya Patel
AWAlison M. Welch
Alison M. Welch
CWCarla Wilson
Carla Wilson
MMMargaret M. Mroz
Margaret M. Mroz
Lisa MaierLisa Maier
Lisa Maier

19 August 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SGSarah A. Greaves
Sarah A. Greaves
ARAvinash Ravindran
Avinash Ravindran
RSRadleigh G. Santos
Radleigh G. Santos
LCLan Chen
Lan Chen
MFMichael T. Falta
Michael T. Falta
AFAndrew P. Fontenot
Andrew P. Fontenot
Löfgren’s syndrome (LS) is an acute form of sarcoidosis characterized by a genetic association with HLA-DRB1*03 (HLA-DR3) and an accumulation of CD4+ T cells of unknown specificity in the bronchoalveolar lavage (BAL). Here, we screened related LS-specific TCRs for antigen specificity and identified a peptide derived from NAD-dependent histone deacetylase hst4 (NDPD) of Aspergillus nidulans that stimulated these CD4+ T cells in an HLA-DR3–restricted manner. Using ELISPOT analysis, a greater number of IFN-γ– and IL-2–secreting T cells in the BAL of DR3+ LS subjects compared with DR3+ control subjects was observed in response to the NDPD peptide. Finally, increased IgG antibody responses to A. nidulans NDPD were detected in the serum of DR3+ LS subjects. Thus, our findings identify a ligand for CD4+ T cells derived from the lungs of LS patients and suggest a role of A. nidulans in the etiology of LS.

1 January 2019 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
IYIvana V. Yang
Ivana V. Yang
IKIain Konigsberg
Iain Konigsberg
KMKristyn MacPhail
Kristyn MacPhail
LLLi Li
Li Li
EDElizabeth J. Davidson
Elizabeth J. Davidson
Lisa MaierLisa Maier
Lisa Maier
Epigenetic marks are likely to explain variability of response to antigen in granulomatous lung disease. The objective of this study was to identify DNA methylation and gene expression changes associated with chronic beryllium disease (CBD) and sarcoidosis in lung cells obtained by BAL. BAL cells from CBD (n = 8), beryllium-sensitized (n = 8), sarcoidosis (n = 8), and additional progressive sarcoidosis (n = 9) and remitting (n = 15) sarcoidosis were profiled on the Illumina 450k methylation and Affymetrix/Agilent gene expression microarrays. Statistical analyses were performed to identify DNA methylation and gene expression changes associated with CBD, sarcoidosis, and disease progression in sarcoidosis. DNA methylation array findings were validated by pyrosequencing. We identified 52,860 significant (P < 0.005 and q < 0.05) CpGs associated with CBD; 2,726 CpGs near 1,944 unique genes have greater than 25% methylation change. A total of 69% of differentially methylated genes are significantly (q < 0.05) differentially expressed in CBD, with many canonical inverse relationships of methylation and expression in genes critical to T-helper cell type 1 differentiation, chemokines and their receptors, and other genes involved in immunity. Testing of these CBD-associated CpGs in sarcoidosis reveals that methylation changes only approach significance, but are methylated in the same direction, suggesting similarities between the two diseases with more heterogeneity in sarcoidosis that limits power with the current sample size. Analysis of progressive versus remitting sarcoidosis identified 15,215 CpGs (P < 0.005 and q < 0.05), but only 801 of them have greater than 5% methylation change, demonstrating that DNA methylation marks of disease progression changes are more subtle. Our study highlights the significance of epigenetic marks in lung immune response in granulomatous lung disease.